Biogen Inc. (NASDAQ:BIIB) Given Average Rating of “Hold” by Brokerages

Biogen Inc. (NASDAQ:BIIB) has received a consensus rating of “Hold” from the twenty-eight analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, fifteen have given a hold recommendation and twelve have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $205.3077.

A number of equities research analysts recently weighed in on BIIB shares. Guggenheim boosted their price target on shares of Biogen from $185.00 to $246.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Canaccord Genuity Group raised their price objective on shares of Biogen from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Wells Fargo & Company lifted their target price on shares of Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a report on Sunday, February 8th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Biogen in a research report on Monday, February 9th. Finally, Morgan Stanley set a $190.00 price target on Biogen in a research note on Sunday, February 8th.

Biogen Price Performance

Biogen stock opened at $183.84 on Tuesday. The business’s 50-day simple moving average is $185.36 and its 200 day simple moving average is $170.24. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The stock has a market cap of $26.98 billion, a price-to-earnings ratio of 20.87, a P/E/G ratio of 1.46 and a beta of 0.15. Biogen has a 12-month low of $110.04 and a 12-month high of $202.41.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same period in the previous year, the business posted $3.44 EPS. The company’s quarterly revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, research analysts anticipate that Biogen will post 15.83 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the sale, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.18% of the company’s stock.

Hedge Funds Weigh In On Biogen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Norges Bank acquired a new stake in shares of Biogen in the 4th quarter valued at approximately $464,408,000. Boston Partners bought a new position in Biogen during the 4th quarter worth approximately $302,815,000. Fred Alger Management LLC grew its holdings in Biogen by 39,074.8% during the fourth quarter. Fred Alger Management LLC now owns 798,774 shares of the biotechnology company’s stock valued at $140,576,000 after purchasing an additional 796,735 shares during the period. Employees Provident Fund Board bought a new stake in Biogen in the fourth quarter valued at approximately $123,931,000. Finally, Orion Porfolio Solutions LLC increased its stake in Biogen by 6,828.4% in the second quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock valued at $64,965,000 after purchasing an additional 509,809 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.